IGMS IGM Biosciences, Inc.Stock Price & Overview
Stock Price & Overview
$16.16
IGMS Stock Price
Quant Ranking
IGMS Analysis
IGMS News
Latest Headlines
Ratings Summary
People Also Follow
Similar to IGMS
ETFs Holding IGMS
IGMS Company Profile
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGMS Revenue
IGMS Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
IGMS Ownership
IGMS Peers
Risk
Technicals
IGMS Transcripts
Investor Presentations
IGMS SEC Filings
Press Releases
IGMS Income Statement
IGMS Balance Sheet
IGMS Cash Flow Statement
IGMS Long Term Solvency
Discover More
You may be interested in: